Last edition
News about "GSK B7-H3 Antibody Drug Conjugate "
GSK Reveals First Global Ris-Rez Data in Small Cell Lung Cancer
GSK has reported first global Ris-Rez data in ES-SCLC, with a 61 percent response rate in a phase 1b trial supporting further clinical development.
GSK B7-H3 Antibody Drug Conjugate | 22/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members